Tag: cpt 81225

Medicare Ends Coverage for Some Pharmacogenomic Testing

By Mary Van Doren, from the Volume XXII NO. 9 - June 22, 2015 issue

CEO SUMMARY: Medicare’s decision to cease covering many pharmacogenomic tests puts as many as 19 million Americans who have genetic variations affecting their response to medications at risk. These medications are commonly prescribed for patients with cardiovascular disease, pain, depression, anxiety, and cancer. Meanwhile, medical centers such as Mayo Clinic are conducting clinical studies to collect evidence that appropriate use of pharmacogenomic tests can improve patient outcomes while also reducing the cost of care.

View Article

Medicare Ends Coverage for Genetic Drug-Sensitivity Tests

By Joseph Burns, from the Volume XXII NO. 9 - June 22, 2015 issue

View Article

Report Shows Price Drop for Most Molecular Tests

By Joseph Burns, from the Volume XX No. 9 - July 8, 2013 issue

CEO SUMMARY: In recent weeks, labs are reporting that Medicare contractors have begun to issue payments for molecular test claims filed—but unpaid—since January 1, 2013. A newly-issued analysis of this situation by Quorum Consulting indicates that, for many molecular assays, Medicare contractors are now paying less than they paid for the same tests last year.

View Article

Volume XXVI No. 8 – June 10, 2019

THE U.S. HAS LOST ALMOST 18% of its pathologists since 2007. This means the U.S. has even fewer pathologists than other countries who have already suffered adverse clinical lab quality events. TDR also digs further into what this means for the industry, finding that while salaries and benefits are increasing, higher pay will come with a heavier workload. Also, in a Clinical Lab 2.0 case study, TDR walks readers through the steps Northwell Health took to help improve patient care – and add value – by using its data to identify patients who were undiagnosed or misdiagnosed.

See the full table of contents

Tag: cpt 81225

Enter Your Login Credentials